tetano
Editor, Senior Moderator
Perfusion
. 2022 Jul 4;2676591221113135.
doi: 10.1177/02676591221113135. Online ahead of print.
Determinants of survival in patients on extracorporeal membrane oxygenation therapy due to severe covid-19
Ruslan Natanov[SUP] 1 [/SUP], Elena R Kunkel[SUP] 1 [/SUP], Olaf Wiesner[SUP] 2 [/SUP], Axel Haverich[SUP] 1 [/SUP], Bettina Wiegmann[SUP] 1 [/SUP], Stefan Rümke[SUP] 1 [/SUP], Christian Kühn[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Severe acute respiratory distress syndrome (ARDS) due to Coronavirus Disease-19 (COVID-19) is associated with high mortality. Although survival on mechanical circulatory support has improved, determinants for better prognosis are still unclear. Here, we report on the outcome of our patient population with the need for mechanical circulatory support due to severe COVID-19 (sCOVID-19) induced ARDS.
Methods: All patients treated with extracorporeal membrane oxygenation (ECMO) for severe ARDS due to sCOVID-19 were analysed. Patients > 18 years of age at the time of initiation of ECMO were included. Pre-existing comorbidities, complications during ECMO implantation, and ECMO runtime were reviewed. The latency to intubation, proning, tracheotomy, and ECMO implantation was analysed. Furthermore, the survival and non-survival population were compared to determine factors in favour of a better outcome.
Results: In total, 85 patients were treated with veno-venous membrane oxygenation (vv-ECMO) for severe ARDS in our medical centre. The patient population was predominantly male (83.5%) with a mean patient age of 54.9 years. A history of cardiovascular disease (p = .01), smoking (p < .05), need for vasopressor- (p < .05), and renal replacement therapy (p < .001) was associated with a worse prognosis. Overall survival was 50%. The survival population was significantly younger (p = .004), had a significantly higher body weight (p = .02) and body mass index (BMI) (p = .01). Furthermore, survival was significantly better when vv-ECMO was initiated within 48 h after admission (p < .001).
Conclusions: Pre-existing cardiovascular disease, higher age, history of nicotine abuse, and development of renal failure are associated with poor outcome. Early start of vv-ECMO therapy may lead to better survival in sCOVID-19 patients, although complications during ECMO therapy are associated with a worse prognosis.
Keywords: acute respiratory distress syndrome; coronavirus disease-19; determinants; extracorporeal membrane oxygenation; respiratory failure.
. 2022 Jul 4;2676591221113135.
doi: 10.1177/02676591221113135. Online ahead of print.
Determinants of survival in patients on extracorporeal membrane oxygenation therapy due to severe covid-19
Ruslan Natanov[SUP] 1 [/SUP], Elena R Kunkel[SUP] 1 [/SUP], Olaf Wiesner[SUP] 2 [/SUP], Axel Haverich[SUP] 1 [/SUP], Bettina Wiegmann[SUP] 1 [/SUP], Stefan Rümke[SUP] 1 [/SUP], Christian Kühn[SUP] 1 [/SUP]
Affiliations
- PMID: 35786064
- DOI: 10.1177/02676591221113135
Abstract
Background: Severe acute respiratory distress syndrome (ARDS) due to Coronavirus Disease-19 (COVID-19) is associated with high mortality. Although survival on mechanical circulatory support has improved, determinants for better prognosis are still unclear. Here, we report on the outcome of our patient population with the need for mechanical circulatory support due to severe COVID-19 (sCOVID-19) induced ARDS.
Methods: All patients treated with extracorporeal membrane oxygenation (ECMO) for severe ARDS due to sCOVID-19 were analysed. Patients > 18 years of age at the time of initiation of ECMO were included. Pre-existing comorbidities, complications during ECMO implantation, and ECMO runtime were reviewed. The latency to intubation, proning, tracheotomy, and ECMO implantation was analysed. Furthermore, the survival and non-survival population were compared to determine factors in favour of a better outcome.
Results: In total, 85 patients were treated with veno-venous membrane oxygenation (vv-ECMO) for severe ARDS in our medical centre. The patient population was predominantly male (83.5%) with a mean patient age of 54.9 years. A history of cardiovascular disease (p = .01), smoking (p < .05), need for vasopressor- (p < .05), and renal replacement therapy (p < .001) was associated with a worse prognosis. Overall survival was 50%. The survival population was significantly younger (p = .004), had a significantly higher body weight (p = .02) and body mass index (BMI) (p = .01). Furthermore, survival was significantly better when vv-ECMO was initiated within 48 h after admission (p < .001).
Conclusions: Pre-existing cardiovascular disease, higher age, history of nicotine abuse, and development of renal failure are associated with poor outcome. Early start of vv-ECMO therapy may lead to better survival in sCOVID-19 patients, although complications during ECMO therapy are associated with a worse prognosis.
Keywords: acute respiratory distress syndrome; coronavirus disease-19; determinants; extracorporeal membrane oxygenation; respiratory failure.